Tobramycin - Generic Drug Details

What are the generic drug sources for tobramycin and what is the scope of patent protection?

Tobramycin is the generic ingredient in eleven branded drugs marketed by Novartis, Viatris, Epic Pharma Llc, Alcon Pharms Ltd, Alembic, Apotex Inc, Bausch And Lomb Inc, Chartwell Rx, Gland, Somerset Theraps Llc, Sandoz, Chiesi, Pulmoflow Inc, Alkem Labs Ltd, Amneal Pharms, Dr Reddys Labs Sa, Hikma, Luoxin Aurovitas, Lupin, Mankind Pharma, Micro Labs, Pharmobedient, Sun Pharm, Teva Pharms Usa, Lilly, Apothecon, Baxter Hlthcare Corp, Eugia Pharma, Fresenius Kabi Usa, Hospira, Igi Labs Inc, Mylan Labs Ltd, Slate Run Pharma, Watson Labs Inc, Xellia Pharms Aps, and Xgen Pharms, and is included in sixty-four NDAs. There are two patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Tobramycin has fifteen patent family members in thirteen countries.

There are eighteen drug master file entries for tobramycin. Thirty-six suppliers are listed for this compound.

Summary for tobramycin

International Patents:	15
US Patents:	2
Tradenames:	11
Applicants:	36
NDAs:	64
Drug Master File Entries:	18
Finished Product Suppliers / Packagers:	36
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	126
Drug Prices:	Drug price trends for tobramycin
Drug Sales Revenues:	Drug sales revenues for tobramycin
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for tobramycin
What excipients (inactive ingredients) are in tobramycin?	tobramycin excipients list
DailyMed Link:	tobramycin at DailyMed

See drug prices for tobramycin

See drug sales revenues for tobramycin

Recent Clinical Trials for tobramycin

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Uppsala Clinical Research Center, Sweden	PHASE4
The Swedish Research Council	PHASE4
Uppsala University	PHASE4

See all tobramycin clinical trials

Pharmacology for tobramycin

Drug Class

Aminoglycoside Antibacterial

Medical Subject Heading (MeSH) Categories for tobramycin

Anti-Bacterial Agents

Anatomical Therapeutic Chemical (ATC) Classes for tobramycin

J01GB	Other aminoglycosides
J01G	AMINOGLYCOSIDE ANTIBACTERIALS
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

S01AA	Antibiotics
S01A	ANTIINFECTIVES
S01	OPHTHALMOLOGICALS
S	Sensory organs

Paragraph IV (Patent) Challenges for TOBRAMYCIN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
BETHKIS	Inhalation Solution	tobramycin	300 mg/4 mL	201820	1	2017-08-31
TOBI	Inhalation Solution	tobramycin	300 mg/5 mL	050753	1	2009-06-29

US Patents and Regulatory Information for tobramycin

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	TOBREX	tobramycin	SOLUTION/DROPS;OPHTHALMIC	050541-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Watson Labs Inc	TOBRAMYCIN SULFATE	tobramycin sulfate	INJECTABLE;INJECTION	062945-001	Aug 9, 1989		DISCN	No	No
Pulmoflow Inc	KITABIS PAK	tobramycin	SOLUTION;INHALATION	205433-001	Dec 2, 2014	AN	RX	No	No

Expired US Patents for tobramycin

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Viatris	TOBI PODHALER	tobramycin	POWDER;INHALATION	201688-001	Mar 22, 2013
Viatris	TOBI PODHALER	tobramycin	POWDER;INHALATION	201688-001	Mar 22, 2013
Chiesi	BETHKIS	tobramycin	SOLUTION;INHALATION	201820-001	Oct 12, 2012

EU/EMA Drug Approvals for tobramycin

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Viatris Healthcare Limited	Tobi Podhaler	tobramycin	EMEA/H/C/002155Tobi Podhaler is indicated for the suppressive therapy of chronic pulmonary infection due to Pseudomonas aeruginosa in adults and children aged 6 years and older with cystic fibrosis. See sections 4.4 and 5.1 regarding data in different age groups.Consideration should be given to official guidance on the appropriate use of antibacterial agents.	Authorised	no	no	no	2011-07-20
Pari Pharma GmbH	Vantobra (previously Tobramycin PARI)	tobramycin	EMEA/H/C/005086Vantobra is indicated for the management of chronic pulmonary infection due to Pseudomonas aeruginosa in patients aged 6 years and older with cystic fibrosis (CF).Consideration should be given to official guidance on the appropriate use of antibacterial agents.	Authorised	no	no	no	2019-02-18
Pari Pharma GmbH	Vantobra	tobramycin	EMEA/H/C/002633Vantobra is indicated for the management of chronic pulmonary infection due to Pseudomonas aeruginosa in patients aged 6 years and older with cystic fibrosis (CF).Consideration should be given to official guidance on the appropriate use of antibacterial agents.	Withdrawn	no	no	no	2015-03-18

International Patents for tobramycin

Country	Patent Number	Title	Estimated Expiration
Australia	2004229512	Aerosolization apparatus with capsule puncture alignment guide
Canada	2520265	APPAREIL DE PULVERISATION EN AEROSOL COMPRENANT UN GUIDE D'ALIGNEMENT POUR PERFORER LA CAPSULE (AEROSOLIZATION APPARATUS WITH CAPSULE PUNCTURE ALIGNMENT GUIDE)
Cyprus	1117408

Supplementary Protection Certificates for tobramycin

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1280520	14/2015	Austria		PRODUCT NAME: TOBRAMYCIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/10/652/001-003 20110720
1273292	C01273292/01	Switzerland		PRODUCT NAME: TOBRAMYCIN; REGISTRATION NO/DATE: SWISSMEDIC 58751 28.05.2009
1280520	92678	Luxembourg		PRODUCT NAME: TOBRAMYCINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE QUI EN DERIVE. FIRST REGISTRATION: 20110725

Last updated: July 30, 2026

Tobramycin market dynamics and financial trajectory: how demand, pricing, and exclusivity shape revenue

Tobramycin’s revenue trajectory is driven by (1) sustained use in cystic fibrosis (CF) airway disease and (2) utilization of inhaled formulations that face periodic formulation and device competition. Market growth is constrained by patent/route-to-market timing, payor pressure, and competitive inhaled antibiotics. Financial performance depends on mix between nebulized and dry powder offerings, formulary status, and competitive entries that can erode unit pricing after exclusivity windows end.

What is tobramycin’s current market structure and where does revenue come from?

Snapshot: Tobramycin is primarily an inhaled antibiotic used for chronic suppressive therapy in CF patients with Pseudomonas aeruginosa. Revenue is concentrated in the U.S., with smaller contributions from Europe and other geographies depending on local formulary coverage and availability of specific inhaled products.

Tobramycin therapeutic role in CF

Tobramycin is used as chronic inhaled suppressive therapy to reduce bacterial burden and exacerbations in CF patients with P. aeruginosa. Demand is tied to:

• CF population size and treated prevalence (diagnosis, survival, and treatment adherence)
• Therapy persistence (repeat cycles, discontinuations, switching)
• Clinical guideline adherence and payer coverage criteria

Product forms that typically anchor revenue

Tobramycin’s market is segmented by route and delivery system:

• Inhaled nebulized solutions (historically dominant in CF)
• Inhaled dry powder/alternative inhalation technologies (where available in-country)
• Oral and topical uses exist but generally do not drive tobramycin’s largest commercial footprint relative to inhaled CF therapy

Competitive set affecting pricing and share

Tobramycin faces substitution pressure from inhaled antibiotics used for chronic or intermittent airway suppression, including:

• Other aminoglycosides and inhaled antimicrobials
• Combination and alternating regimens deployed by CF clinicians
• Newer pipeline entries that can shift payer preference

How do pricing, reimbursement, and payer policies affect tobramycin revenues?

Tobramycin revenue is sensitive to net price because inhaled antibiotics are frequently subject to:

• High rebate intensity in managed care
• Prior authorization and step edits
• Formulary tier placement that changes with competing products

What drives net price vs list price

Net realization for inhaled drugs is typically impacted by:

• Contracting and rebate structures
• Indication-specific restrictions (CF subsets)
• Pharmacy benefit management positioning
• Use of “therapeutic equivalence” policies for generics or authorized copies when exclusivity expires

Pharmacy channel dynamics

• Specialty pharmacy distribution is common for CF inhaled antibiotics.
• Patient support programs can improve persistence and reduce churn, but they do not fully offset pricing pressure when competitors enter.

When does tobramycin lose exclusivity, and what does that mean for financial trajectory?

Exclusivity timing determines when the market shifts from brand-protected pricing to lower-cost competition. The revenue impact is usually lumpy:

• Pre-expiration: share held by brand during last-cycle prescribing
• At/after expiration: rapid competitive share loss if authorized generics or generics enter
• Post-entry: pricing stabilizes at lower net levels but volumes can partially offset revenue decline

How tobramycin exclusivity mechanics translate to revenue

Key drivers include:

• Patent expiration dates by dosage form and delivery system
• Regulatory exclusivities (if applicable by product history)
• The strength and timing of any Paragraph IV filings (when relevant)

Generic entry risk profile

Inhaled antibiotics face manufacturing and delivery-system barriers. Even when active ingredient patents expire, competition may hinge on:

• Device equivalence requirements
• Performance consistency in aerosolization and dosing delivery
• Formulation patents that can delay generic approvals or restrict substitution

What patents protect tobramycin inhaled products, and how strong is the estate?

Tobramycin’s patent protection is typically layered:

• Composition-of-matter patents on tobramycin and related salts/complexes (where applicable by specific product)
• Formulation and particle/aerosol performance patents for inhaled delivery
• Method-of-use patents tied to CF regimens
• Delivery device and manufacturing process patents for consistent dose administration

Patent estate strength that matters commercially

From a revenue-risk perspective, the most commercially determinative patents are those that:

• Block approval of an inhaled generic or “authorized copy”
• Protect delivery-system performance characteristics that payors and clinicians treat as clinically necessary
• Extend exclusivity beyond the earliest composition patent expiration

How to assess strength in practice

Companies typically evaluate:

• Remaining years-to-expiration by jurisdiction
• Claim breadth (is it limited to a specific formulation or more general?)
• Litigation history that indicates enforceability
• Whether settlement agreements constrain generic entry dates

What FDA regulatory status applies to tobramycin, and how does it shape competition?

The FDA approval pathway influences timing and entry risk. Tobramycin inhaled products are typically listed in the Orange Book with patent and exclusivity information that governs generic and AB-rated substitution dynamics.

Orange Book listings and patent-protection implications

For each marketed tobramycin product, Orange Book:

• Lists active ingredients and approved dosage forms
• Connects products to listed patents (drug substance, drug product, and method-of-use)
• Shows exclusivity periods (if any) tied to the FDA approval history

AB-rated interchangeability and substitution

Commercial substitution hinges on:

• AB rating for generics and whether they are pharmaceutically equivalent
• Pharmacy and payer policies allowing switching without prior authorization
• Patient tolerance and device comfort, particularly for inhaled therapies

How does tobramycin compare with competing inhaled antibiotics in market impact?

Tobramycin competes inside the inhaled antibiotic class used for CF airway suppression. The financial outcome depends on relative advantages across:

• Dose regimen convenience
• Perceived tolerability and tolerability management protocols
• Formulary preference and contract value
• Switching costs tied to delivery devices

Competitive scenarios that change revenue trajectory

• Switching toward alternative inhaled antibiotics when payors incentivize preferred agents
• Cost-driven substitutions after generic entry or authorized copies
• Regimen optimization by CF clinicians that changes relative cycles among inhaled antibiotics

Which companies hold tobramycin revenue exposure, and what are the likely financial inflections?

Revenue exposure is typically held by:

• Brand originators and their licensees
• Authorized generics or marketers post-exclusivity
• In some cases, specialty distributors and CF-focused channel partners (less direct revenue risk, but meaningful influence on prescribing)

Financial inflection points investors track

• Loss of formulary status or major payer contract renegotiations
• Patent-driven settlement constraints that delay generic entry
• Product discontinuations or consolidation among inhaled formulations

How many patent-labeled products are at stake, and how does that map to revenue?

Tobramycin’s commercial “at risk” universe typically includes multiple labeled forms under different product applications and delivery formats. The revenue mapping is driven by:

• Which specific dosage forms generate the majority of spend
• Which forms have later-expiring patents or device-specific protection
• Which products have active litigation or Paragraph IV activity that can accelerate entry

Revenue mapping method used in market-risk analysis

• Identify Orange Book listed tobramycin products by strength and dosage form
• Tie each to patent and exclusivity dates
• Overlay expected generic entry scenarios
• Convert likely share changes into revenue impacts using channel and payer adoption curves

What patent litigation and settlements affect tobramycin market timing?

Inhaled antibiotic markets often see disputes tied to:

• Whether generic formulations infringe listed patents
• Whether certain patents are invalid or unenforceable
• Settlement terms that can impose “launch-at-risk” windows or entry delays

What settlement terms typically change financially

Settlements can change:

• Earliest permitted generic launch date
• Scope of products that are allowed to enter (specific strengths, device configurations, or indications)
• Carve-outs that keep certain SKUs protected longer than the earliest expiration

What generic entry risks exist for tobramycin and what barriers can slow erosion?

Generic competition is not purely time-based. For inhaled antibiotics, barriers include:

• Manufacturing controls that demonstrate consistent aerosol performance
• Device equivalence and dosing delivery to meet FDA standards
• Formulation or process patents that remain in force past active ingredient expiry

Barriers that can extend pricing pressure timelines

• Delivery system patents
• Formulation-specific patent claims
• Device performance litigation that slows AB rating adoption

How does tobramycin revenue typically evolve by year: pre-expiration, launch, and post-launch?

A typical revenue pattern for a protected inhaled antibiotic:

1. Pre-expiration plateau: brand holds share; price discipline by payors offsets some volume growth
2. Launch-year volatility: generic entry timing can cause abrupt share movement
3. Post-launch stabilization: net price declines; volume may partially recover if overall CF population growth persists
4. Re-optimization: competitors adjust contracting and rebates; brand may defend through patient support, switching programs, or contracting concessions

Key Takeaways

• Tobramycin’s financial trajectory is anchored by chronic CF use and sustained dosing persistence, with growth constrained by payor pressure and substitution within inhaled antibiotics.
• Net revenue is most sensitive to formulary status, rebate intensity, and delivery-system competition, not just underlying demand.
• Exclusivity and patent estate timing shape when pricing erodes; delivery-device and formulation patents can delay or complicate generic entry.
• Patent litigation and settlements can produce step-function changes in market share at the SKU level.
• Competitive dynamics within inhaled CF antibiotics determine whether revenue declines are volume-offset or mainly price-driven.

FAQs

1. Does tobramycin’s revenue depend more on volume growth or net price erosion after generic entry?
2. How do Orange Book patent listings for tobramycin dosage forms translate into generic launch timing?
3. What role do delivery devices and formulation performance play in inhaled tobramycin generic viability?
4. Which payer policies most affect persistence and switching behavior for CF inhaled antibiotics like tobramycin?
5. How do patent litigation settlement terms typically influence the effective launch date for competing tobramycin products?

References

1. FDA Orange Book. “Approved Drug Products with Therapeutic Equivalence Evaluations.” U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
2. FDA. “Drug Approval Reports.” U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approval-reports
3. FDA. “Paragraph IV Patent Certifications.” U.S. Food and Drug Administration. https://www.fda.gov/drugs/competition-economics-and-patents/drug-patent-information-and-interactions